Shots:

•  The BT designation is based on seven clinical studies evaluating safety and efficacy for allergens including peanut- milk- egg and others
• The BT designation for Xolair (omalizumab) is to prevent severe allergic reactions following accidental exposure to one or more foods in people with allergies
• Genentech and Novartis are working with NIAID and the Consortium of Food Allergy Research (CoFAR) initiating a pivotal study for evaluating the efficacy and safety of Xolair in multiple food allergies. Additionally- Genentech and Novartis are working to co-develop and co-promote Xolair

/ article | Ref: Roche | Image: Forbes